Prevalence of Anemia in End Stage Renal Disease Patients on Maintenance Hemodialysis

Anemia in End Stage Renal Disease

Authors

  • Rafia Mazhar MCH Center Hajiani Fatima, Hyderabad, Pakistan
  • Bhagwan Das Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
  • Santosh Kumar Jinnah Sindh Medical University, Karachi, Pakistan
  • Muhammad Tassaduq Khan Dow University Hospital, Karachi, Pakistan
  • Sapna Bai MCH Center Hajiani Fatima, Hyderabad, Pakistan
  • Babeeta Hinduja Dow University Hospital, Karachi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v4i06.860

Keywords:

Anemia, End Stage Renal Disease, Maintenance Hemodialysis

Abstract

Anemia is a significant complication in patients with End Stage Renal Disease (ESRD), leading to increased morbidity, mortality, and reduced quality of life, particularly in that undergoing maintenance hemodialysis. Objective: To determine the frequency of anemia in ESRD patients receiving maintenance hemodialysis. Methods: This descriptive cross-sectional study enrolled consecutively all patients aged 18 to 70 years, of both genders, with ESRD on maintenance hemodialysis. Anemia was defined as a hemoglobin concentration below 13.0 g/dl in men and postmenopausal women, and below 12.0 g/dl in other women, based on diagnoses from the last three months. Baseline and predictor variables, including age, gender, duration of ESRD, duration of hemodialysis, and various laboratory parameters (hemoglobin, MCV, serum iron level, serum TIBC level, ferritin level, and Tsf level) were observed. Results: The study included 196 patients, with a mean age of 54.76 ± 10.38 years. Of these, 71 (36.2%) were females and 125 (63.8%) were males. The mean duration of ESRD was 5.71 ± 0.92 months, mean corpuscular volume (MCV) was 86.92 ± 13.66, serum iron level was 40.82 ± 5.23, serum total iron-binding capacity (TIBC) level was 220.82 ± 43.13. Anemia was present in 57.7% of patients. Conclusions: This study revealed a significantly higher prevalence of anemia in ESRD patients undergoing maintenance hemodialysis. These results highlight the significance of managing anemia in these patient population in order to improve outcomes and raise their quality of life.

References

Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Primary care: Clinics in Office Practice. 2008 Jun; 35(2): 329-44. doi: 10.1016/j.pop.2008.01.008. DOI: https://doi.org/10.1016/j.pop.2008.01.008

Stauffer ME and Fan T. Prevalence of anemia in chronic kidney disease in the United States. PloS One. 2014 Jan; 9(1): e84943. doi: 10.1371/journal.pone.0084943. DOI: https://doi.org/10.1371/journal.pone.0084943

Ahmed S, Jafri L, Khan AH. Evaluation of'CKD-EPI Pakistan'equation for estimated glomerular filtration rate (eGFR): a comparison of eGFR prediction equations in Pakistani population. Journal of the College of Physicians and Surgeons--Pakistan. 2017 Jul; 27(7): 414.

Anees M and Ibrahim M. Anemia and hypoalbuminemia at initiation of hemodialysis as risk factor for survival of dialysis patients. Journal of College of Physicians and Surgeons Pakistan. 2009 Dec; 19(12): 776-80.

Saran R. US renal data system. 2018 USRDS annual data report: epidemiology of kidney disease in the United States. American Journal of Kidney Diseases. 2019; 73(1): Svii-xxii. doi: 10.1053/j.ajkd.2019.01.002. DOI: https://doi.org/10.1053/j.ajkd.2019.01.002

Centers for Disease Control and Prevention (CDC). Chronic kidney disease surveillance system—United States. 2019. [Last Cited: 4th Jul 2023]. Available at: https://nccd.cdc.gov/ckd/

Alam A, Amanullah F, Baig-Ansari N, Lotia-Farrukh I, Khan FS. Prevalence and risk factors of kidney disease in urban Karachi: baseline findings from a community cohort study. BMC Res Notes. 2014 Mar; 7: 179. doi: 10.1186/1756-0500-7-179. DOI: https://doi.org/10.1186/1756-0500-7-179

Genovesi S, Valsecchi MG, Rossi E, Pogliani D, Acquistapace I, De Cristofaro V, et al. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrology Dialysis Transplantation. 2009 Aug; 24(8): 2529-36. doi: 10.1093/ndt/gfp104. DOI: https://doi.org/10.1093/ndt/gfp104

Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International. 2013 Jan; 3(1): 5-14.

Babitt JL and Lin HY. Mechanisms of anemia in CKD. Journal of the American Society of Nephrology: JASN. 2012 Sep; 23(10): 1631. doi: 10.1681/ASN.2011111078. DOI: https://doi.org/10.1681/ASN.2011111078

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. Journal of the American Society of Nephrology. 2001 Dec; 12(12): 2768-74. doi: 10.1681/ASN.V12122768. DOI: https://doi.org/10.1681/ASN.V12122768

Gillespie BS, Inrig JK, Szczech LA. Anemia management in chronic kidney disease. Hemodialysis International. 2007 Jan; 11(1): 15-20. doi: 10.1111/j.1542-4758.2007.00147.x. DOI: https://doi.org/10.1111/j.1542-4758.2007.00147.x

Anees M, Hussain Y, Ibrahim M, Ilahi I, Ahmad S, Asif KI, et al. Outcome of chronic kidney disease patients on the basis of referral to nephrologist: a one-year follow-up study. Journal of the College of Physicians and Surgeons Pakistan. 2018 Apr; 28(4): 304-8. doi: 10.29271/jcpsp.2018.04.304. DOI: https://doi.org/10.29271/jcpsp.2018.04.304

McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Current Medical Research and Opinion. 2004 Sep; 20(9): 1501-10. doi: 10.1185/030079904X2763. DOI: https://doi.org/10.1185/030079904X2763

Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney International. 2002 May; 61: S35-8. doi: 10.1046/j.1523-1755.61.s80.7.x. DOI: https://doi.org/10.1046/j.1523-1755.61.s80.7.x

Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleveland Clinic Journal of Medicine. 2006 Mar; 73(3): 289-97. doi: 10.3949/ccjm.73.3.289. DOI: https://doi.org/10.3949/ccjm.73.3.289

Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. American Journal of Health-System Pharmacy. 2007 Jul; 64(13_Supplement_8): S3-7. doi: 10.2146/ajhp070181. DOI: https://doi.org/10.2146/ajhp070181

Zarychanski R and Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? Cmaj. 2008 Aug; 179(4): 333-7. doi: 10.1503/cmaj.071131. DOI: https://doi.org/10.1503/cmaj.071131

McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anaemia among pre‐ESRD patients with chronic kidney disease. European Journal of Clinical Investigation. 2005 Dec; 35: 58-65. doi: 10.1111/j.1365-2362.2005.01532.x. DOI: https://doi.org/10.1111/j.1365-2362.2005.01532.x

Jia L, Dong X, Yang J, Jia R, Zhang H. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Annals of translational medicine. 2019 Dec; 7(23): 720. doi: 10.21037/atm.2019.12.18. DOI: https://doi.org/10.21037/atm.2019.12.18

Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment. Journal of the American Society of Nephrology. 2020 Mar; 31(3): 456-68. doi: 10.1681/ASN.2019020213. DOI: https://doi.org/10.1681/ASN.2019020213

Downloads

Published

2023-06-30
CITATION
DOI: 10.54393/pjhs.v4i06.860
Published: 2023-06-30

How to Cite

Mazhar, R. ., Das, B. ., Kumar, S. ., Khan, M. T. ., Bai, S. ., & Hinduja, B. . (2023). Prevalence of Anemia in End Stage Renal Disease Patients on Maintenance Hemodialysis: Anemia in End Stage Renal Disease. Pakistan Journal of Health Sciences, 4(06), 130–133. https://doi.org/10.54393/pjhs.v4i06.860

Issue

Section

Original Article

Plaudit